{"transactions":[{"id":4635912,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:02:57.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":10340,"price":6.8372,"value":70696.648,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":312744,"source":{"system":"sec-edgar","filing":"0001193125-26-415531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526415531/ownership.xml","form_type":"4"}},{"id":4616446,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-11T22:36:49.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":120000,"derivative":{"exercise_price":10.79,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193125-26-389512","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389512/ownership.xml","form_type":"4"}},{"id":4616445,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-09-11T22:36:49.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":323084,"source":{"system":"sec-edgar","filing":"0001193125-26-389512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389512/ownership.xml","form_type":"4"}},{"id":4321,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-09-04T20:04:03.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":10366,"price":11.1555,"value":115637.913,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":283084,"source":{"system":"sec-edgar","filing":"0001193125-26-383625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526383625/ownership.xml","form_type":"4"}},{"id":772230,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-05-20T01:52:09.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":7002,"price":9.0078,"value":63072.6156,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $9.0078, and the range of prices were between $8.7421 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":293450,"source":{"system":"sec-edgar","filing":"0001193125-26-231509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526231509/ownership.xml","form_type":"4"}},{"id":897102,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:50:20.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2187,"price":4,"value":8748.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":300452,"source":{"system":"sec-edgar","filing":"0001193125-26-057672","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057672/ownership.xml","form_type":"4"}},{"id":897101,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:50:20.000Z","date":"2026-02-15","kind":"grant","planned":false,"acquired":true,"shares":117300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":302639,"source":{"system":"sec-edgar","filing":"0001193125-26-057672","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526057672/ownership.xml","form_type":"4"}},{"id":971343,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":13.47,"expiration_date":"2034-05-01","underlying":"Common Stock","underlying_shares":20519},"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971342,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9119,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vesting is monthly over a 48-month period starting May 24, 2023 in equal monthly amounts."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":9119},"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971341,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":77519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares vested on December 31, 2022, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":5.01,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":77519},"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":971340,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2025-12-13T00:20:38.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":107156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I."}],"balance_after":185339,"source":{"system":"sec-edgar","filing":"0001193125-25-317982","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525317982/ownership.xml","form_type":"4"}},{"id":997881,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2025-11-18T01:39:06.000Z","date":"2025-11-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1899,"price":3.25,"value":6171.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":78183,"source":{"system":"sec-edgar","filing":"0001193125-25-285008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312525285008/ownership.xml","form_type":"4"}},{"id":1064078,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2025-08-19T00:15:05.000Z","date":"2025-08-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":3577,"price":2.75,"value":9836.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":80082,"source":{"system":"sec-edgar","filing":"0001415889-25-022220","document":"form4-08182025_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588925022220/form4-08182025_080801.xml","form_type":"4"}},{"id":1064077,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2025-08-19T00:15:05.000Z","date":"2025-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1341,"price":2.13,"value":2856.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards."}],"balance_after":83659,"source":{"system":"sec-edgar","filing":"0001415889-25-022220","document":"form4-08182025_080801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588925022220/form4-08182025_080801.xml","form_type":"4"}},{"id":1238683,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2025-02-28T22:15:11.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":85000,"source":{"system":"sec-edgar","filing":"0001415889-25-006035","document":"form4-02282025_050206.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588925006035/form4-02282025_050206.xml","form_type":"4"}},{"id":1407741,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Tech Operations Officer"}}],"security":"Common Stock","published_at":"2024-09-13T20:15:17.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001415889-24-023362","document":"form4-09132024_040908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588924023362/form4-09132024_040908.xml","form_type":"4"}},{"id":3252163,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:30.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-20-001622","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001622/primarydocument.xml","form_type":"4"}},{"id":3252162,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Restricted Stock Unit","published_at":"2020-02-24T19:32:30.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":53333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":53333},"source":{"system":"sec-edgar","filing":"0001562180-20-001622","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001622/primarydocument.xml","form_type":"4"}},{"id":3252161,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:30.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":65000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.42,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-20-001622","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001622/primarydocument.xml","form_type":"4"}},{"id":3252160,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-24T19:32:30.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":10.14,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001562180-20-001622","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001622/primarydocument.xml","form_type":"4"}},{"id":3252159,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Common Stock","published_at":"2020-02-24T19:32:30.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":21400,"price":18.75,"value":401250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 1,551 shares of Dermira Common Stock acquired by the Reporting Person on November 15, 2019 pursuant to Dermira's Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001622","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218020001622/primarydocument.xml","form_type":"4"}},{"id":3516434,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-05-21T16:04:07.000Z","date":"2019-05-17","kind":"exercise","acquired":false,"shares":26667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the total number of shares underlying the restricted stock unit grant will vest on May 17, 2019 (the \"Initial Vest Date\") and 1/3 of the shares underlying the RSU grant will vest each year thereafter until full vested, subject to the award recipient continuing to be a \"Service Provider\" (as defined in the Plan) through the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/3 of the total number of shares underlying the restricted stock unit grant will vest on May 17, 2019 (the \"Initial Vest Date\") and 1/3 of the shares underlying the RSU grant will vest each year thereafter until full vested, subject to the award recipient continuing to be a \"Service Provider\" (as defined in the Plan) through the applicable vesting dates."}],"balance_after":53333,"derivative":{"underlying":"Common Stock","underlying_shares":26667},"source":{"system":"sec-edgar","filing":"0001562180-19-003028","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218019003028/primarydocument.xml","form_type":"4"}},{"id":3516433,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Common Stock","published_at":"2019-05-21T16:04:07.000Z","date":"2019-05-17","kind":"tax_withholding","acquired":false,"shares":9222,"price":10.5,"value":96831.0,"ownership":{"direct":true},"balance_after":19849,"source":{"system":"sec-edgar","filing":"0001562180-19-003028","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218019003028/primarydocument.xml","form_type":"4"}},{"id":3516432,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Common Stock","published_at":"2019-05-21T16:04:07.000Z","date":"2019-05-17","kind":"exercise","acquired":true,"shares":26667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include prior ESPP purchases."}],"balance_after":29071,"source":{"system":"sec-edgar","filing":"0001562180-19-003028","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218019003028/primarydocument.xml","form_type":"4"}},{"id":3655944,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-02-14T19:58:31.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-19-001001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218019001001/primarydocument.xml","form_type":"4"}},{"id":3655943,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2019-02-14T19:58:31.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on February 1, 2019, subject to the continuing employment of the Reporting person on the applicable vesting date."}],"balance_after":65000,"derivative":{"exercise_price":7.42,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-19-001001","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218019001001/primarydocument.xml","form_type":"4"}},{"id":3940546,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Restricted Stock Unit","published_at":"2018-05-09T18:16:30.000Z","date":"2018-05-07","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the total number of shares underlying the restricted stock unit grant will vest on May 17, 2019 (the \"Initial Vest Date\") and 1/3 of the shares underlying the RSU grant will vest each year thereafter until full vested, subject to the award recipient continuing to be a \"Service Provider\" (as defined in the Plan) through the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock"}],"balance_after":80000,"derivative":{"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-18-002432","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218018002432/primarydocument.xml","form_type":"4"}},{"id":3940545,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10004,"kind":"person","name":"Horan Christopher","position":1,"cik":"0001736819","reported_name":"Horan Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Ops Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2018-05-09T18:16:30.000Z","date":"2018-05-07","kind":"grant","acquired":true,"shares":140000,"price":10.14,"value":1419600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option grant will vest on April 2, 2019 and 1/48th of the total number of shares underlying the option grant will vest monthly thereafter, subject to the award recipient continuing to be a \"Service Provider\" (as defined in the Plan) through the applicable vesting dates."}],"balance_after":140000,"derivative":{"exercise_price":10.14,"expiration_date":"2028-05-06","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001562180-18-002432","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557883/000156218018002432/primarydocument.xml","form_type":"4"}}]}